Innovac Therapeutics, a Massachusetts-based mRNA vaccine developer, has announced the successful completion of its Pre-Series A financing round, raising $18 million. The funding was led by Lichen Capital, Vision Plus Capital, Couplet Health fund, TG Sino-Dragon Fund, and other investors. The proceeds from this round will be directed towards the development of the company’s mRNA technology platform and the construction of manufacturing capacity.
Establishment of Scientific Advisory Board (SAB)
In conjunction with the financing round, Innovac Therapeutics has established its Scientific Advisory Board (SAB) to provide strategic guidance and scientific expertise. The SAB includes distinguished members such as Dr. David Bernstein, Dr. Shan Lu, and Dr. Elaine Mardis, who bring a wealth of experience and knowledge to the company.
Implications for mRNA Vaccine Development and Manufacturing
The funding and the establishment of the SAB are significant milestones for Innovac Therapeutics as it advances its mRNA technology. The investment will support the company’s efforts to develop innovative mRNA vaccines and build the necessary manufacturing capabilities to bring these vaccines to market. With the backing of a strong investor group and the guidance of its SAB, Innovac Therapeutics is well-positioned to contribute to the growing field of mRNA-based therapeutics and vaccines.-Fineline Info & Tech
